BioSpace News Archive

Workplace friendships are important for good company culture. According to a new study, most employees feel lonely at the workplace which ruins their productivity.

Lawmakers continue to hear concerns over drug prices, as well as proposals to fix the issue.

After the U.S. Food and Drug Administration (FDA) took a hard line on the use of real-world evidence in clinical trials, industry leaders are beginning to back the idea, but with some minor changes.

Across parts of Europe, Asia and the rest of the globe, pharma and biotech companies have made strides and deals to advance their pipelines and technologies this week.

There’s no doubt that drug prices, particularly sky-high prices for new biologics and companies jacking up the prices of older drugs, is a problem. And it’s definitely a political issue, especially now that candidates are declaring their plans to run for president in 2020.

History shows just how slow public health officials, the federal government, regulators and pharmaceutical companies were to respond to the emergence of HIV in the 1980s. The reasons are numerous—it was a puzzling viral disease, it first appeared in what was then a largely stigmatized patient population, gay men, and there weren’t really any existing treatments for viral diseases.

Microbix Biosystems Inc. reports results for its first quarter of fiscal 2019, the three-month period ending December 31, 2018 (“Q1"), with lower sales, improving percentage gross margin, improving and positive cash flow from operations and progress toward its operational goals.

London-based Clinigen Group pc will now have full rights to Proleukin (aldesleukin, human recombinant interleukin-2). This morning, the U.K.-based pharmaceutical and services company struck a deal with Novartis to acquire the U.S. rights to the metastatic renal cell carcinoma treatment.

Johnson & Johnson plunked down $3.4 billion in cash to acquire privately held Auris Health, Inc., a company that developed robotic endoscopic technologies that can be used in the treatment of lung cancer.

In October, 5AM Ventures announced plans to raise $350 million for its sixth fund and it seems that the company has hit its mark. The money in that fund will be used to support the formation and development of new biotech companies.